Vitiligo – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Vitiligo

Vitiligo – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Vitiligo is a chronic (long-lasting) disorder that causes areas of skin to lose color. When skin cells that make color are attacked and destroyed, the skin turns a milky-white color. Vitiligo is due to the loss or destruction of melanocytes, which are the cells that produce melanin. Melanin determines the colour of skin, hair, and eyes. If melanocytes cannot form melanin or if their number decreases, skin colour becomes progressively lighter.

Thelansis Epidemiology research study indicates Vitiligo approximately Affecting 0.5-1% of the population worldwide. Competitive landscape of Vitiligo includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Vitiligo across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Vitiligo Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing , Market Event and Product Event , Country specific Forecast Model, Market uptake and patient share uptake , Attribute Analysis , Analog Analysis , Disease burden and pricing scenario, Summary and Insights.

 

Read more: Vitiligo – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

S. No        Asset        Company        Stage

1        SHR0302 Ointment BID        Reistone Biopharma Company Limited        Phase 3

2        Ruxolitinib cream        Incyte Corporation        Phase 2

3        Cerdulatinib 0.37% gel        Dermavant Sciences GmbH        Phase 2

4        Afamelanotide        Clinuvel Pharmaceuticals Limited        Phase 2

5        ATI-50002 topical solution        Aclaris Therapeutics, Inc.        Phase 2

6        Afamelanotide        Clinuvel Pharmaceuticals Limited        Phase 2

7        AS012        Sun Pharma Global FZE        Phase 2

8        PF-06651600        Pfizer        Phase 2

9        Apremilast        Celgene        Phase 2

10        Abatacept        Bristol-Myers Squibb        Phase 1

11        Application of pimecrolimus        Novartis        Phase 2